Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study
- Marasco G.
- Colecchia A.
- Bacchi Reggiani M. L.
- Celsa C.
- Farinati F.
- Giannini E. G.
- Benevento F.
- Rapaccini G. L.
- Caturelli E.
- Di Marco M.
- Biasini E.
- Marra F.
- Morisco F.
- Foschi F. G.
- Zoli M.
- Gasbarrini A.
- Baroni G. S.
- Masotto A.
- Sacco R.
- Raimondo G.
- Azzaroli F.
- Mega A.
- Vidili G.
- Brunetto M. R.
- Nardone G.
- Dajti E.
- Ravaioli F.
- Avanzato F.
- Festi D.
- Trevisani F.
DOIAbstract
Background: Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients. Aims: To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. Methods: The performance of several prognostic scores was assessed through a Cox regression-model evaluating the C-index and the Akaike Information Criterion (AIC). Results: Data of 1129 patients were analyzed. The mean age of patients was 61.6 years, and 80.8% were male. During a median follow-up period of 13 months, 789 patients died. The media...
Add to ORKG